Somatostatin analogs target the somatostatin receptors that are overexpressed in patients with glucagonoma and thus manage to achieve a reduction in the release of glucagon in the blood and a shrinking of the tumor, which leads to an improvement in symptoms such as hyperglycemia or necrolytic migratory erythema [172]. This evidence concerns the gene GCG and Hyperglycemia.